Vir Biotechnology (NASDAQ:VIR) Upgraded to Hold at Zacks Inv

Vir Biotechnology (NASDAQ:VIR – Get Rating) was upgraded by Zacks Investment Research from a “strong sell” rating to a “hold” rating in a report issued on Friday, Zacks.com reports. According to Zacks, “Vir Biotechnology Inc. is a clinical-stage immunology company. It is focused on combining immunologic insights to treat and prevent serious infectious diseases. The […]

Related Keywords

Arizona , United States , San Francisco , California , Annm Hanly , Robertw Baird , Vickil Sato , , Vir Biotechnology Inc , Asset Management Inc , Vir Biotechnology Company Profile Get Rating , Securities Exchange Commission , Zacks Investment Research , Needham Company , Profund Advisors , Asset Management Americas Inc , Macquarie Group Ltd , Vir Biotechnology , Get Rating , Director Vicki , Exchange Commission , State Retirement System , Management Inc , Management Americas , Macquarie Group , Biotechnology Company Profile , Nasdaq Vir , Ivir , Medical , Upgrade ,